Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 17/20 | 0.79 |
| ▸ | ESRRB | O95718 | 1/20 | 0.79 |
| ▸ | ESR1 | P03372 | 1/20 | 0.79 |
| ▸ | ESRRG | P62508 | 1/20 | 0.79 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8163017 | 1.00 | ESRRA (0.79) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648930 | 1.00 | ESRRA (0.79) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2380995 | 0.94 | ESRRA (0.85) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL8156842 | 0.94 | ESRRA (0.85) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2380997 | 0.94 | ESRRA (0.85) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL4434858 | 0.91 | ESRRA (0.67) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL4434856 | 0.91 | ESRRA (0.67) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL8158774 | 0.89 | ESRRA (0.81) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL8164211 | 0.89 | ESRRA (0.78) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2383285 | 0.89 | ESRRA (0.81) | ESRRAESRRBESR1ESRRGESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062051-B2 | Compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders | GALAPAGOS NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9034852-B2 | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-05-19 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| US-8809267-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8344009-B2 | Substituted phenoxy thiazolidinediones as estrogen related receptor-á modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-01 | — | — | US | disclosed |
| US-20120108571-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | GAUL MICHAEL (US) | 2012-05-03 | — | — | US | disclosed |
| US-8119669-B2 | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-21 | — | — | US | disclosed |
| EP-2132188-B1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLEDINEDIONE AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-14 | — | — | EP | disclosed |
| US-20090111855-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080286265-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| WO-2008109727-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109731-A2 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLEDINEDIONE AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JASSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
| EP-1678153-A1 | THIOZOLIDINONES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042516-A2 | LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005042505-A1 | THIOZOLIDINONES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111855-A1 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS | ESR2, ESRRA, ESRRG | ESRRA 2/4885ESRRB 4/4885ESR1 6/4885 |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | FGF2, CCNA2, VEGFA | ESRRA 1254/4885ESRRB 591/4885ESR1 1842/4885 |
| US-20120108571-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | ESRRA 2/4885ESRRB 4/4885ESR1 7/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ESRRA 4698/4885ESRRB 4717/4885ESR1 4094/4885 |
| US-20080286265-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | ESRRA 2/4885ESRRB 4/4885ESR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.